Stephen L. Hoerter's most recent trade in ORIC Pharmaceuticals Inc was a trade of 40,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ORIC Pharma Inc | Stephen L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| MBX Biosciences Inc | Stephen L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2025 | 8,000 | 8,000 | - | - | Stock option (right to buy) | |
| MBX Biosciences Inc | Stephen L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2025 | 100,000 | 100,000 | - | - | Stock option (right to buy) | |
| MBX Biosciences Inc | Stephen L. Hoerter | Director | Purchase of securities on an exchange or from another person at price $ 13.25 per share. | 17 Oct 2025 | 20,000 | 20,000 | - | 13.2 | 264,984 | Common Stock |
| C4 Therapeutics Inc | Stephen L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 35,500 | 35,500 | - | - | Stock Option (Right to Buy) | |
| MBX Biosciences Inc | Stephen L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 16,000 | 16,000 | - | - | Stock option (right to buy) | |
| MBX Biosciences Inc | Stephen L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2025 | 32,000 | 32,000 | - | - | Stock option (right to buy) | |
| ORIC Pharma Inc | Stephen L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 35,000 | 35,000 | - | - | Stock Option (right to buy) |